Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamnestic Immune Response 4–6 Years After Primary HBVAXPRO Vaccination in Children
2006-001639-23Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Recombivax HB and Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Merck & Co. Primary endpoint: Seroprotection rate at 4 weeks post-booster. Started Jun 2006; status: completed.
02
Drugs
Recombivax HBHepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2006-001639-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001639-23.